Get started

PFIZER

Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA NodPfizer PFE announced that the FDA has granted approval to its oral, once-daily pill called etrasimod to treat moderately-to-severely active ulcerative colitis (UC). The oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator will be marketed by the brand name of Velsipity (2 mg dose). The approval for etrasimod was based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12. These studies evaluated the safety and efficacy of a daily 2mg dose of oral etrasimod in UC patients who had failed treatment with a JAK inhibitor. Both studies achieved their primary endpoint of clinical remission over placebo and all key secondary endpoints. An application seeking the approval of etrasimod is also under review in the EU, with a decision from the European Medicines Agency anticipated in first-half 2024. Velsipity (etrasimod) was added to Pfizer’s inflammation and immunology portfolio with the March 2022 acquisition of Arena Pharmaceuticals. The oral, once-daily pill for UC, a chronic condition, is an advanced therapy, which, if approved, will offer patients an opportunity to achieve steroid-free remission. Pfizer’s stock has declined 37.4% so far this year against an increase of 8.5% for the industry.
NYSE:PFELong
by DEXWireNews
Pfizer's Stock: Is it Worth the Investment ?Pfizer's Stock: Is it Worth the Investment Amidst Challenges and Opportunities? Pfizer, a pharmaceutical powerhouse, has made headlines in recent years, primarily for its groundbreaking coronavirus vaccine. Despite achieving over $100 billion in annual revenue last year, the company's stock has witnessed a significant decline of approximately 35% in the current year. This prompts the question: Why has Pfizer's share price dipped despite robust financial performance, and is it still a worthwhile investment? In this article, we'll delve into the factors affecting Pfizer's stock and assess whether it presents an attractive investment opportunity. Challenges on the Horizon The decline in Pfizer's stock can be attributed to investor concerns regarding the sustainability of vaccine sales in a post-pandemic world. As vaccine demand wanes, the company faces declining revenues from products like Comirnaty and Paxlovid, with projections of double-digit revenue declines compared to the previous year. Moreover, Pfizer is grappling with the imminent patent expirations of key drugs like Eliquis and Ibrance, which could result in revenue losses totaling $17 billion from 2025 through 2030. Assessing the Risks Pfizer's transition from government contracts to commercial sales introduces some risk, as commercial purchasers typically do not commit to extensive supply agreements years in advance. Additionally, the looming patent cliff poses a revenue challenge that Pfizer must address. Positive Developments Despite these challenges, Pfizer has several positive developments to consider. Comirnaty and Paxlovid may still provide steady recurring revenue, albeit at lower levels. Pfizer envisions the coronavirus market evolving into something akin to the flu shot market, potentially generating substantial billion-dollar revenue, given its market leadership. Earnings from coronavirus-related products have empowered Pfizer to pursue acquisitions and initiatives to fuel long-term growth. Last year, Pfizer acquired four companies expected to contribute over $10 billion to revenue by 2030. Furthermore, a planned acquisition of oncology specialist Seagen could add an additional $10 billion in revenue. Addressing the patent cliff, Pfizer is actively working to mitigate revenue losses. It anticipates generating $20 billion in revenue by 2030 from ongoing product launches. The company is midway through its most substantial wave of product releases, aiming for 19 launches in an 18-month period, with contributions expected in the latter half of this year. Pfizer projects that business deals, ongoing product launches, and potential pipeline launches could result in non-coronavirus revenue of up to $84 billion in 2030. Is Pfizer a Worthy Investment? Considering these factors, Pfizer appears well-prepared to offset potential revenue losses and foster growth in the years ahead. The revenue outlook for 2030 is promising, even without factoring in coronavirus product sales. Additionally, Pfizer's shares are currently trading at an attractive valuation of around 10 times forward earnings estimates. In conclusion, Pfizer seems to be a prudent investment choice at this juncture. While immediate stock price gains may not be expected, investors entering at the current price point may enjoy dividends in the near term, as Pfizer is committed to rewarding shareholders. Furthermore, the potential for improved share price performance in the future makes Pfizer a compelling investment opportunity amidst its transitional phase. Previous ( Winning ) Idea:
NYSE:PFEShort
by FOREXN1
6
PFIZER Buy signal but only on the short-term.Pfizer (PFE) has been trading within a Channel Down pattern since the start of the year and on Friday it registered the strongest green 1D candle since the recent Lower Low leg started in August. This is technically the start of the new rebound leg towards a new Lower High. Those have been priced within the 1D MA50 (blue trend-line) and 1D MA100 (green trend-line), never breaking above the latter. We are therefore targeting the 1D MA50 again at 34.50, an average estimate based on the previous three Lower High legs. Note that this is only a short-term trade as the long-term trend remains heavily bearish within the Channel Down. Only a 1D candle closing above the 1D MA100 can justify a longer term buy targeting the 1D MA200 (orange trend-line). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:PFELong
by TradingShot
6
Pfizer (PFE) -> It Is Now Or NeverMy name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️ I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise. This is how you build real long term wealth! In today's anaylsis I want to take a look at the bigger picture on Pfizer. At the moment Pfizer stock is once again retesting major sructure at the psychological $33 level which already acted as pretty strong support in the past. Considering that the next support level below current price is at $27, Pfizer is now trading at a pretty decisive potential turning point and has not yet broken structure towards the downside. - - - - - - - - - - - - - - - - - - - - I know that this is a quite simple trading approach but over the past 4 years I've realized that simplicity and consistency are much more important than any trading strategy. Keep the long term vision🫡
NYSE:PFELong
by SwingTraderPhilTV
18
PFE, Huge Triangle-Formation With Possible Breakout Ahead!Hello Traders Investors And Community, welcome to this analysis where we are looking at the 4-hour timeframe perspective of stock value PFIZER, the recent events, the current formation structure, what needs to be fulfilled that the stock confirms properly and what are possible trading opportunities when the stock has confirmed. As the main stock-market has recovered from the huge corona-breakdowns seen this year there where stock which gained strength out of the crisis and stocks which just stayed in a bearish state, although the health sector surged in demand because of the health crisis and people wanting to live more sustainable lives PFIZER is still somewhat in a sideways movement where it has to confirm and therefore show the ability that it has the strength to move beyond this sideways correction, therefore, I detected some important and interesting signals which can determine the follow-up destiny. When looking at my chart you can watch this huge possible ascending-triangle-formation where the stock already confirmed several times the upper and lower boundary, furthermore, it noted several times above the 100- and 400-EMA which you can watch marked in blue and orange in the chart, this is a good sign because on the other side there are stocks which trading below these EMA structures. As the stock is approaching the upper boundary another time now we can expect it to confirm as resistance and therefore move on to test the lower boundary of the triangle-formation another time, when the stock manages to stabilize in this boundary where also a coherent support-cluster lies as you can watch it in my chart the potential is given that the stock goes on to confirm the huge ascending--triangle-formation with a final break above it which will cause the bullish rising and an appointment to higher targets. For now, it is highly important that the stock holds the substantially lower boundary sustainable and does not fall below it where the possibility is not big currently but it should by no means kept by side easily. Compared to other stocks which already moved above and confirmed new highs this stock has definitely some room to go, the breakout when it happens can be traded the best way with a conservative entry after the upper boundary has confirmed, it is also possible to open up an immediate position but this would be the riskier variety, traders should decide according to individual risk preference, and to secure the proper confirmation it is from high importance that corona increases not heavily again and the real economic situation stabilizes further from the heavy breakdowns because when it does not this can cause bearish rumors in all global markets and therefore possible downside ahead which can invalidate the scenario. In this manner, thank you for watching, support for more market insight, have a great day, and all the best to you! There are many roads to prosperity, but one must be taken. Information provided is only educational and should not be used to take action in the markets.
NYSE:PFE
by VincePrince
9
PFE - Pfizer drop from medain line.Here's not much on the chart. But what you see is evident. The pitchforks median line is respected by price many times. And this time it's the same. But there's a reason why this time price could flush down to the L-MLH. Indexes are weaker and weaker. The first profit target for me is either the L-MLH, or the A/R (yellow) line. The Action/Reaction line is projected from above's swing range. So, there we have another one to the short side. I have more short charts than longs. However, I always try to keep my overall portfolio balanced. How? There are always industries and sectors which perform to the long side, even when markets tank. It's simple but it takes effort.
NYSE:PFEShort
by HowToChart
Covid 2023 - Profiting from CorruptionHello everyone Josh here again. I’m sure by now you’ve already heard mumblings of Covid’s imminent return. We are seeing everything from colleges to hospitals start to implement Covid policies. The news cycle is starting to warn of a dangerous flu season/Covid return. Governments around the world are now updating their Covid policies and sleepy Joe’s White House is still pushing for the mass vaccination and experimentation on of human guinea pigs around the world. With all this being said, it is my idea that we are about to go back into lockdown/full Covid policy mode. Although I wish this was not the case, I do intend to profit from it. Illustrated is the Moderna chart, I use this, as it was one of the first assets I made money off of during the last pandemic, in fact, you can still go back and see my old idea on my page about Moderna when I called it at around sub $60. However, this could’ve been any chart from Amazon and Netflix to hospital sectors, to e-commerce platforms like Shopify. Basically, anything that will go up during a full-scale, pandemic/lockdown. If my gut feeling is right, and we are going to go into a full-scale lock down, it might be one of the easiest plays of the century. During the last pandemic, we saw airlines, cruise lines, casinos and resorts and a myriad of other sectors collapse to unprecedented lows. I expect something similar to happen this time around, to varying degrees of severity. Many people made millions by shorting assets last pandemic, I think we are setting ourselves up for the perfect storm to profit. Look for stocks to long and short. Ignore the noise and make your money off of the lies of the global elite. Below is an AI rendered breakdown of this idea. Thank you so much for reading. Please follow and like my ideas :) Investment Thesis: Navigating Pandemic-Related Market Trends I. Introduction: The investment thesis centers around capitalizing on potential market shifts resulting from pandemic-related policies enacted by governments and corporations globally. II. Market Outlook: Anticipating the implementation of pandemic-related rules and regulations, which could include mask mandates, lockdowns, and travel restrictions. III. Asset Allocation Strategy: A. Long Positions: E-commerce Dominance: As witnessed during the previous pandemic, e-commerce platforms like Amazon thrived. This trend is likely to persist as people turn to online shopping for convenience and safety. Entertainment Streaming: Companies like Netflix benefited from increased demand for home entertainment. Expect this trend to continue, making streaming platforms potentially profitable investments. Pharmaceutical Giants: Pfizer and Moderna played pivotal roles in vaccine development during the Covid pandemic. Their expertise positions them well for potential future vaccine requirements or pharmaceutical innovations. Healthcare Stocks: Hospital and healthcare-related stocks may experience increased demand as health services remain crucial during pandemic periods. B. Short Positions: Travel and Hospitality Sectors: Historical data shows that airlines, cruise liners, resorts, and casinos experienced significant declines during the last pandemic due to travel restrictions and reduced consumer spending. IV. Risk Considerations: While historical patterns suggest certain sectors will benefit and others may decline during pandemics, unforeseen variables can impact market dynamics. Careful monitoring and adaptability are essential. V. Diversification and Hedging: To mitigate risks, consider diversifying your portfolio across industries and asset types. This approach helps balance potential losses from short positions with gains from long positions. VI. Exit Strategy: Regularly reassess the investment landscape, keeping an eye on shifts in policies, vaccination rates, and economic indicators. Be prepared to adjust your positions accordingly to optimize gains or minimize losses. VII. Conclusion: In light of potential pandemic-related policies, a strategic investment approach involves capitalizing on e-commerce, streaming, pharmaceutical, and healthcare sectors, while shorting travel and hospitality sectors. Prudent risk management, diversification, and a proactive exit strategy will be pivotal in navigating the ever-evolving market landscape. Please note that investment decisions involve inherent risks, and it's advisable to consult with a qualified financial advisor before executing any investment strategy.
NASDAQ:MRNA
by Helios_Capital_Investment
Unveiling the Potential of Pfizer Pharmaceutical Stock in 2023Are you searching for a lucrative investment opportunity that promises great returns in 2023? Look no further as we unveil the hidden potential of Pfizer Pharmaceutical stock. In this blog post, we will delve into the compelling reasons why investing in Pfizer is not only a smart move but also an incredibly exciting. From groundbreaking innovations to robust financial performance, join us as we explore why Pfizer is poised to be a game-changer in the pharmaceutical industry and how you can reap substantial rewards by including it in your investment portfolio. Don’t miss out on this exclusive insight into what could be your most profitable venture yet! Monthly price action is supporting a strong bullish correction in the following months. Pfizer is one of the world’s leading pharmaceutical companies and was at the forefront of developing a vaccine for Covid-19 in 2020. The stock price reflected the impact of the vaccine until December 2021, when the stock plunged, losing almost 50% of its value. It’s then when a longer-term demand imbalance takes control and helps us make a high-probability decision to buy and hold shares of Pfizer PFE stock.
NYSE:PFE
by AlfonsoMoreno
Pfizer getting ready to make rapid movesPfizer is one of the world’s leading pharmaceutical company specializes in vaccines, hospitals, internal medicines and inflammation and immunology. Their manufacturing capacity is 4 billion tablets annually and supplied in neighboring countries of India. Pfizer CMP is 3866. Negative aspects of the company are high valuation (P.E. = 28.3), MFs are decreasing stake. Positive aspects of the company are increasing annual net profits, improving cash from operations annual, no debt, FIIs are increasing stake and zero promoter pledge. Entry can be taken after closing above 3901. Targets in the stock will be 3975 and 4006. Long term target in the stock will be 4069 and 4129. Stop loss in the stock should be maintained at closing below 3696.
NSE:PFIZERLong
by Happy_Candles_Investment
Pfizer to stall at major resistance?Pfizer - Medium Term - We look to Sell at 39.88 (stop at 41.08) Bespoke resistance is located at 40. 40.14 has been pivotal. 40.37 has been pivotal. Daily signals are bearish. We look for a temporary move higher. Our profit targets will be 37.08 and 36.58 Resistance: 37.05 / 38.30 / 39.00 Support: 36.03 / 35.50 / 35.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group.
NYSE:PFEShort
by VantageMarkets
PFE | Time to Load | LONGPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
NYSE:PFELong
by DivergenceSeeker
1
Pfizer's Quest for GLP-1 Dominance: A Potential Game-ChangerOver the past year, investors have been disappointed with Pfizer as the company's stock experienced a significant decline of 28.8%. This decline can be attributed, in part, to the anticipated drop in sales for Pfizer's COVID-19 vaccine, Comirnaty, and its antiviral treatment, Paxlovid. However, there is an overlooked aspect that investors have failed to recognize: Pfizer's potential as a promising "oasis stock." In contrast, certain companies such as Eli Lilly, Crispr Therapeutics, Microsoft, and Nvidia have garnered significant investor interest since the beginning of 2023, leading to their shares outperforming the broader market. These companies share a common thread of being associated with cutting-edge technologies like artificial intelligence, gene editing, or weight-loss treatments, which have captured the attention of investors. Despite Pfizer's extensive $70 billion spending spree on business development in recent years, the company has struggled to impress Wall Street as of late. This sentiment is reinforced by the fact that Pfizer's stock currently trades at a remarkably undervalued forward-looking earnings yield of 9.2%. This valuation is considerably lower compared to other major pharmaceutical stocks, which have an average earnings yield of 7%, as well as the 10-year U.S. Treasury bond, which yields 3.73%. Fundamentally, investors have not fully embraced Pfizer's compelling value proposition, which revolves around the potential for the company to become a powerhouse in areas such as immunology, rare blood disorders, and cancer treatment by the end of the decade. However, a specific set of clinical assets may soon captivate the market's attention and potentially alter this situation: the oral glucagon-like peptide-1 receptor (GLP-1) agonists, danuglipron and lotiglipron. Danuglipron has recently displayed outstanding results in a mid-stage trial, showing promise as a dual treatment for controlling blood sugar and promoting weight loss in individuals with type 2 diabetes. Pfizer, the pharmaceutical giant, is patiently awaiting the forthcoming mid-stage trial data for lotiglipron before determining which candidate to advance into phase 3 testing. The significance of this lies in the fact that shares of Eli Lilly and Novo Nordisk have experienced substantial upward trends over multiple years, primarily driven by their GLP-1 drugs, tirzepatide and semaglutide, respectively. These innovative medications are expected to generate annual sales of nearly $100 billion due to the increasing prevalence of diabetes and obesity worldwide. While Pfizer is entering the GLP-1 market relatively later, its oral offerings have the potential to effectively compete against injectable drugs like tirzepatide and semaglutide in the long run. Following the release of danuglipron's impressive mid-stage trial data, Cantor Fitzgerald, a financial services firm, has reiterated its price target of $75 per share for Pfizer's stock. This target represents a potential increase of approximately 94% compared to the current stock price. In contrast, most other firms covering Pfizer have adopted a more cautious approach, choosing to wait for phase 3 data from one of the GLP-1 candidates before revising their fair value estimates. This cautious stance is understandable, as mid-stage data often do not reliably predict the outcomes of late-stage trials. Additionally, by the time Pfizer enters the GLP-1 market, tirzepatide and semaglutide may have already established themselves as strong competitors. What does this mean? It suggests that Pfizer possesses a pipeline asset for type 2 diabetes and weight loss that is not fully recognized by the market. It is likely that the pharmaceutical company will have late-stage trial data on either danuglipron or lotiglipron ready for presentation by 2025, paving the way for a commercial launch in 2026. The bottom line is that if Pfizer can develop a GLP-1 asset that surpasses the clinical performance of the current market leaders, it has the potential to create one of the best-selling drugs in history. In such a scenario, Cantor Fitzgerald's ambitious price target, though premature at the moment, may not seem far-fetched in about three years. For investors who are willing to take a more aggressive stance, considering Pfizer as a leading big pharma stock in the near future could prove worthwhile. It's worth noting that the success of Pfizer's GLP-1 assets hinges on the outcome of late-stage trials and their ability to compete effectively with established competitors like tirzepatide and semaglutide. Market dynamics, regulatory approvals, and other factors can also impact the commercial viability of these drugs. Therefore, investors should exercise caution and conduct thorough research before making any investment decisions. Overall, while Pfizer has faced challenges and a decline in stock performance, its potential in the GLP-1 market and other therapeutic areas cannot be overlooked. The company's long-term prospects, driven by innovative treatments and strategic investments, could lead to significant growth and value creation in the coming years.
NYSE:PFE
by FOREXN1
7
PFE - Buy The Dip or Follow The Trend?When I began research for this post I expected to be giving the bull case for Pfizer. It's the type of stock I like - a household name oozing with quality and prestige, a strong moat, beaten up with strongly bearish sentiment with multiple factors pointing towards recovery, with short term technical support and long term positive fundamental outlook. I like to play the contrarian in the stock market and it often pays well. So what about Pfizer? Well, technically it's RSI oversold (or was on Thursday, before a small bump Friday) on virtually every timeframe from the 1 hour right through to the Weekly. Looking at Measured Moves, something I do regularly, it's down 19 points from it's swing high on Dec 14th 2022, exactly the same as big upswing from Feb 25th to Aug 18th 2021, and just short of the Oct 13th to Dec 20th 2021 swing of 21 points. Note that these 3 swings mentioned are the largest swings in Pfizer history, due to the growth and subsequent crash caused by COVID and the following recovery. We also have the potential for an area of support here, with the area around 36 having seen both support and resistance on a regular basis since 2016, and if we zoom out a year or 2 and look at Volume Profile, depending on where your set your Visible Range you're going to see the point of control landing between 34.5 - 36. Either the current price or just below. So what's the problem? There are a few. "Patent Cliffs" are always an issue for pharmaceutical companies, where after 20 years their patents expire and they have to face competition from generic brands entering the space. Five of Pfizer’s products face patent expiration in the next six years — Eliquis, an anticoagulant medication, Ibrance to treat breast cancer, Xeljanz for arthritis, Xtandi for prostate cancer, and Vyndaqel for transthyretin amyloid cardiomyopathy. Excluding Pfizer's COVID sales, these 5 products respresent 40% of the company's sales. Just this week, William Pao, Pfizer’s chief development officer raised concerns about antitrust regulators cracking down on Mergers and Acquisitions, notably with the blockage of Amgen's $28billion takeover of Horizon. This raises questions about Pfizer's proposed $43billion purchase of Seagen, and whether they too will come under regulator scrutiny. Financially, Pfizer's revenue is expected to meaningfully decline in 2023, mainly due to a drop in COVID-19 related sales. Analysts estimate the revenue to be around $68.1B, a 32% YoY decrease. Pfizer's adjusted EPS for FY23 is expected to be $3.37, down 49% YoY, according to Wall Street estimates. This is a company that since 2000 has traded as low as 12 in 2008, to as high as 61 at the peak of the COVID drug mania. While technically we do look likely to see a relief rally in the near term, this isn't a company I want to be exposed to. There is too much uncertainty, and while it may look cheap on the scale of the last few years, we must bear in mind that those years were drastically inflated due to COVID drugs that are no longer relevent to it's financials. Pfizer is coming back down to earth with a thud, and I think the company belongs in the 27-36 price range until we see more clarity on it's Seagen purchase and how much it's revenues are pilfered by competing generics. No play for me right now on Pfizer. This is the reality of stock analysis - you go down the rabbit hole, and ultimately most stocks are neither a buy or a sell. Just a "wait and see".
NYSE:PFE
by HayeTrading
10
PFE | Recession Proof Stock | Fundamental and Technical analysisNYSE:PFE Pfizer Inc. (PFE) is a leading pharmaceutical company with a diverse portfolio of drugs and products, including vaccines, oncology, and rare disease treatments. The successful rollout of COVID-19 vaccines has been a significant driver of Pfizer's revenue growth, with revenue increasing from HKEX:41 billion in 2020 to HKEX:81 billion in 2021 and $100 billion in 2022. Historically, healthcare demand has been relatively stable during economic downturns, as consumers prioritize their health even in times of financial hardship. While the COVID-19 pandemic has caused unprecedented disruption in the healthcare industry and the broader economy, Pfizer's strong financial position and focus on critical healthcare products and services position the company well for long-term success. Based on my short-term technical analysis, I have a bearish target price of TP1: HKEX:37 and TP2: $34.5 and a bullish target price of TP1: TASE:TASECTORBALANCE and TP2: $46.50. It's important to consider both technical and fundamental factors, as well as the broader economic and industry-specific trends when making investment decisions. Overall, Pfizer's strong revenue growth, diverse portfolio of products, and focus on innovation and development suggest a strong outlook for the company. While the ongoing impacts of the COVID-19 pandemic and related public health measures should be monitored, Pfizer's financial strength and history of innovation position the company well for long-term success in the healthcare industry.
NYSE:PFE
by shkspr
2
💉 Pfizer, Inc. Goes Bearish | 44, 39 and 34 Coming NextThe PFE stock, Pfizer, Inc., looks like is about to take a deep dive... Going red... Let's have a look! The most obvious signal is the weekly candle today moving below EMA50, telling us that this stock is preparing to drop for months. Pfizer, Inc. peaked December 2021. In mid-December 2022 PFE printed the inverted hammer bearish candlestick pattern or shooting star. This candlestick came at a long-term lower high (Dec. 2022 vs Dec. 2021). Trading volume has been decreasing since November 2020. The RSI has moved below 50, now bearish, and is trending down strong. The next and at the same time critical support level is 48.24. If this level breaks, PFE is going to move to 39.91 as a new low with even lower possible, but this level is the main one. Bearish target of 39.91 at 0.618 Fib. retracement level followed by 0.786 or 33.98. There is something going on at Twitter as well... I don't know... Do your own research... Not only about trading but also about your health. Thank you for reading. Namaste.
NYSE:PFEShort
by MasterAnanda
1
Pfizer Stock: More Than Just COVID-19 VaccinesYou may be familiar with the negative sentiment surrounding Pfizer, with many citing the company's heavy reliance on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid as a cause for concern. In addition to this, several of Pfizer's top-selling drugs will face patent expirations in the near future, leading many to believe that the company's stock will suffer. While there are certainly challenges facing Pfizer, the conclusion that its stock will suffer is flawed. Despite the company's current predicament, there is a lot to be excited about. Let's explore why Pfizer's stock is becoming increasingly attractive. Over the past five weeks, Pfizer has received a string of positive news. The U.S. Food and Drug Administration (FDA) approved Cibinqo for the treatment of adolescents with atopic dermatitis, marking a significant milestone for the company's growth strategy. Additionally, a late-stage study evaluating the combination of Talzenna and Xtandi to treat metastatic castration-resistant prostate cancer produced positive results, reducing the risk of disease progression or death by 37%. Furthermore, Pfizer announced that regulatory applications for elranatamab had been accepted by the FDA and the European Medicines Agency for the treatment of multiple myeloma. The company expects FDA approval to be granted later this year. In addition, an FDA advisory committee voted to approve Pfizer's respiratory syncytial virus (RSV) vaccine for older adults, which could open up a major market opportunity for the company. On March 10, the FDA approved Zavzpret for the treatment of migraine. Pfizer acquired the drug as part of its purchase of Biohaven in 2022. The company also announced plans to acquire Seagen for $43 billion, which caused Pfizer's stock to rise significantly. The acquisition will provide Pfizer with four approved cancer drugs and promising antibody-drug conjugates (ADCs) that could generate $10 billion in risk-adjusted revenue by 2030. Despite all of these positive developments, Pfizer's stock remains undervalued by investors. Its price is still nearly 35% below its late 2021 high, trading at just 12 times expected earnings. However, the company's dividend has risen to 4.1%, its highest level since mid-2021. Investors seem to be fixated on the difficulties associated with COVID-19 and its treatment, but Pfizer predicts that even on this front, there is good news to come. The company expects demand for Comirnaty to rise to 98 million doses by 2026 due to the launch of the combination flu vaccine COVID. Additionally, demand for Paxlovid is predicted to grow steadily over the next few years, with the possibility of promoting antiviral therapy in China. In conclusion, while there are certainly challenges facing Pfizer, the outlook for the company's stock is better than many people think. Despite the conventional wisdom that Pfizer's stock will suffer, the company is making significant strides towards achieving its goals. Investors should take note of the recent positive developments and consider investing in this pharmaceutical giant.
NYSE:PFEShort
by FOREXN1
8